DK0941333T3 - Immunogent detoksificeret mutant E. Coli LT-A-toksin - Google Patents

Immunogent detoksificeret mutant E. Coli LT-A-toksin

Info

Publication number
DK0941333T3
DK0941333T3 DK97910583T DK97910583T DK0941333T3 DK 0941333 T3 DK0941333 T3 DK 0941333T3 DK 97910583 T DK97910583 T DK 97910583T DK 97910583 T DK97910583 T DK 97910583T DK 0941333 T3 DK0941333 T3 DK 0941333T3
Authority
DK
Denmark
Prior art keywords
coli
toxin
immunogenically
subunit
amino acid
Prior art date
Application number
DK97910583T
Other languages
English (en)
Inventor
Mariagrazia Pizza
Marzia Monica Giuliani
Rino Rappuoli
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Application granted granted Critical
Publication of DK0941333T3 publication Critical patent/DK0941333T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97910583T 1996-10-31 1997-10-30 Immunogent detoksificeret mutant E. Coli LT-A-toksin DK0941333T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622660.0A GB9622660D0 (en) 1996-10-31 1996-10-31 Immunogenic detoxified mutant toxin

Publications (1)

Publication Number Publication Date
DK0941333T3 true DK0941333T3 (da) 2006-01-02

Family

ID=10802210

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97910583T DK0941333T3 (da) 1996-10-31 1997-10-30 Immunogent detoksificeret mutant E. Coli LT-A-toksin

Country Status (10)

Country Link
US (2) US20030113338A1 (da)
EP (2) EP0941333B1 (da)
JP (2) JP3715326B2 (da)
AT (1) ATE303441T1 (da)
CA (1) CA2268758C (da)
DE (1) DE69734110T2 (da)
DK (1) DK0941333T3 (da)
ES (1) ES2247622T3 (da)
GB (1) GB9622660D0 (da)
WO (1) WO1998018928A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EP1486215A3 (en) * 1997-03-21 2006-04-12 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6219776B1 (en) 1998-03-10 2001-04-17 Billions Of Operations Per Second Merged array controller and processing element
IL142284A0 (en) 1998-10-09 2002-03-10 Biogen Inc A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
DE69939943D1 (de) * 1998-10-21 2009-01-02 Kitasato Inst Attenuierte Toxine als Adjuvantien
WO2000037609A2 (en) * 1998-12-22 2000-06-29 Boyce Thompson Institute For Plant Research At Cornell Orally immunogenic bacterial enterotoxins expressed in transgenic plants
AU2002305914A1 (en) * 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
SG178002A1 (en) 2006-10-20 2012-02-28 Biogen Idec Inc Treatment of demyelinating disorders
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
CA2748788C (en) 2009-01-05 2021-02-09 Epitogenesis Inc. The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
SA114350400B1 (ar) 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
US8241608B2 (en) * 2010-03-23 2012-08-14 Development Center For Biotechnology Treating allergy with detoxified E. coli heat-labile enterotoxin
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012058072A1 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc Method of rapidly producing vaccines for animals
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
DK2654784T3 (da) 2010-12-22 2017-02-13 Wyeth Llc Stabile immunogene sammensætninger af staphylococcus aureus-antigener
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2013066665A1 (en) 2011-10-19 2013-05-10 Harrisvaccines, Inc Method of rapidly producing improved vaccines for animals
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
ES2933127T3 (es) 2012-12-20 2023-02-01 Pfizer Procedimiento de glucoconjugación
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
ES2702325T3 (es) 2014-03-11 2019-02-28 Univ Minnesota Vacunas contra el virus de la diarrea epidémica porcina y métodos de uso de las mismas
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
TWI807252B (zh) 2015-05-04 2023-07-01 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2019217473A1 (en) * 2018-05-07 2019-11-14 The Administrators Of The Tulane Educational Fund Mutant e. coli enterotoxins as anti-inflammatory agents
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US12570700B2 (en) 2020-04-17 2026-03-10 Regents Of The University Of Minnesota SARS-CoV-2 spike receptor binding domain and compositions and methods thereof
CA3192786A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
AU2022239051A1 (en) * 2021-03-19 2023-10-12 Mie University Pharmaceutical composition for ameliorating acute lung injury and acute worsening of pulmonary fibrosis
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8333131D0 (en) * 1983-12-12 1984-01-18 Glaxo Group Ltd Microbiological process
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
ATE127347T1 (de) 1989-04-28 1995-09-15 Sclavo Spa Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
IT1248735B (it) 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
CA2331832A1 (en) 1998-05-08 1999-11-18 University Of Bristol E.coli heat-labile enterotoxin subunit b (etxb) as an immunomodulator
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン

Also Published As

Publication number Publication date
CA2268758A1 (en) 1998-05-07
ES2247622T3 (es) 2006-03-01
GB9622660D0 (en) 1997-01-08
JP2005247868A (ja) 2005-09-15
WO1998018928A1 (en) 1998-05-07
EP0941333B1 (en) 2005-08-31
ATE303441T1 (de) 2005-09-15
US7291588B2 (en) 2007-11-06
EP1571214A2 (en) 2005-09-07
DE69734110T2 (de) 2006-06-29
EP1571214A3 (en) 2006-03-29
CA2268758C (en) 2007-05-29
JP3715326B2 (ja) 2005-11-09
JP2001508286A (ja) 2001-06-26
EP0941333A1 (en) 1999-09-15
DE69734110D1 (de) 2005-10-06
US20030170262A1 (en) 2003-09-11
US20030113338A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
GB9622660D0 (en) Immunogenic detoxified mutant toxin
DK0835314T3 (da) Immunogen detoksificeret mutant af koleratoksiner
ITMI913513A1 (it) Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ATE187078T1 (de) Nichttoxisches schleimhautadjuvans
CA2131729A1 (en) Helicobacter pylori proteins useful for vaccines and diagnostics
NZ500159A (en) Detoxified mutants of bacterial adp-ribosylating toxins as parenteral adjuvants
CA2437899A1 (en) Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
DK1047784T3 (da) Neissera meningitidis-antigener
ATE229978T1 (de) Helicobacter proteine und impstoffe
AU4267093A (en) Vaccine compositions for mucosal delivery
CA2154063A1 (en) Treatment of h. pylori associated gastroduodenal disease
ATE183241T1 (de) Impstoff gegen streptococcus suis-infektion
CY1110327T1 (el) DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ
DE69510858D1 (de) Mukosale Verabreichung von Pneumokokken-Antigenen